(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.
Mbx Biosciences's earnings in 2026 is -$104,292,000.On average, 13 Wall Street analysts forecast MBX's earnings for 2026 to be -$151,054,141, with the lowest MBX earnings forecast at -$176,516,384, and the highest MBX earnings forecast at -$140,073,639. On average, 13 Wall Street analysts forecast MBX's earnings for 2027 to be -$193,314,625, with the lowest MBX earnings forecast at -$212,386,023, and the highest MBX earnings forecast at -$173,097,017.
In 2028, MBX is forecast to generate -$213,488,890 in earnings, with the lowest earnings forecast at -$257,695,042 and the highest earnings forecast at -$78,380,556.